February 13, 2026 · Form 4 insider transaction
Gano Kyle bought 20,142 shares of Neurocrine Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.; The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.